Regulatory Perspectives on clinical Trials Endpoints

First Page		Document Content
Date: 2008-12-19 09:51:11 Respiratory therapy Asthma Salmeterol Budesonide/formoterol Formoterol Long-acting beta-adrenoceptor agonist Fluticasone/salmeterol Mometasone/formoterol Pulmonology Medicine Combination drugs		Regulatory Perspectives on clinical Trials Endpoints Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 69,04 KB Share Document on Facebook

	As at AugustAstraZeneca’s Environmental Risk Summaries As part of AstraZeneca’s ongoing commitment to environmental data transparency, this website provides environmental risk summaries for the Active Pharmace DocID: 1rlq4 - View Document
	Virginia Asthma Action Plan School Division: ________________________________________________________________________ Name Date of Birth DocID: 1oNoo - View Document
	European Respiratory Disease Volume 8 • Issue 1 • Spring 2012 • Extract Improved Localised Lung Delivery Using DocID: 1ooQZ - View Document
	ORIGINAL CONTRIBUTION How Conducting a Clinical Trial Affects Physicians’ Guideline Adherence and Drug Preferences Morten Andersen, MD, PhD DocID: 1aqMg - View Document
	19th International Congress on Modelling and Simulation, Perth, Australia 12–16 December 2011 http://mssanz.org.au/modsim2011 Trends in Chronic Obstructive Pulmonary Disease Hospitalization Rates in TexasS. DocID: 182ik - View Document